140 related articles for article (PubMed ID: 37222086)
41. Response rate to a single dose of vinblastine administered to dogs with treatment-naive multicentric lymphoma.
Harding K; Bergman N; Smith A; Lindley S; Szivek A; Milner R; Brawner W; Lejeune A
Vet Comp Oncol; 2018 Dec; 16(4):636-641. PubMed ID: 30117260
[TBL] [Abstract][Full Text] [Related]
42. Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma.
Saba CF; Thamm DH; Vail DM
J Vet Intern Med; 2007; 21(1):127-32. PubMed ID: 17338160
[TBL] [Abstract][Full Text] [Related]
43. Hodgkin lymphoma: MOPP chemotherapy to PD-1 blockade and beyond.
Ansell SM
Am J Hematol; 2016 Jan; 91(1):109-12. PubMed ID: 26505486
[TBL] [Abstract][Full Text] [Related]
44. [Semen preservation and gonadal toxicity in the treatment of non Hodgkin lymphoma. Experience at the Gustave-Roussy Institute from 1980 to 1993].
Naccache P; Decaudin D; Koscielny S; Bendahmane B; Auger J; Munck JN
Bull Cancer; 1996 Apr; 83(4):307-14. PubMed ID: 8680082
[TBL] [Abstract][Full Text] [Related]
45. Third-line salvage chemotherapy in Hodgkin's disease.
Bonadonna G; Viviani S; Valagussa P; Bonfante V; Santoro A
Semin Oncol; 1985 Mar; 12(1 Suppl 2):23-5. PubMed ID: 2579440
[TBL] [Abstract][Full Text] [Related]
46. Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
Kelly KM; Hutchinson RJ; Sposto R; Weiner MA; Lones MA; Perkins SL; Massey V;
Ann Oncol; 2002; 13 Suppl 1():107-11. PubMed ID: 12078889
[TBL] [Abstract][Full Text] [Related]
47. Drug selection in the treatment of Hodgkin's disease.
Bonadonna G; Santoro A
Hematol Oncol; 1983; 1(1):3-12. PubMed ID: 6203820
[No Abstract] [Full Text] [Related]
48. MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease.
Connors JM; Klimo P
Semin Hematol; 1987 Apr; 24(2 Suppl 1):35-40. PubMed ID: 2438780
[TBL] [Abstract][Full Text] [Related]
49. [The practice of chemotherapy with the DeVita protocol].
Gassmann W; Schmitz N; Löffler H
Dtsch Med Wochenschr; 1982 Jul; 107(27):1063-9. PubMed ID: 6177488
[No Abstract] [Full Text] [Related]
50. [Clinical and therapeutic aspects of non-Hodgkin lymphoma with primary digestive localization].
Stoica I; Gociu M; Moţoiu I; Coliţă D; Berceanu S
Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Med Interna; 1984; 36(1):11-8. PubMed ID: 6203154
[No Abstract] [Full Text] [Related]
51. Combinaed chemotherapy with cyclophosphamide, vinblastine, procarbazine, and prednisone (CVPP) for patients with advanced Hodgkin's disease. An alternative program to MOPP.
Bloomfield CD; Weiss RB; Fortuny I; Vosika G; Kennedy BJ
Cancer; 1976 Jul; 38(1):42-8. PubMed ID: 947533
[TBL] [Abstract][Full Text] [Related]
52. Doxorubicin alone or in combination with asparaginase, followed by cyclophosphamide, vincristine, and prednisone for treatment of multicentric lymphoma in dogs: 121 cases (1987-1995).
Valerius KD; Ogilvie GK; Mallinckrodt CH; Getzy DM
J Am Vet Med Assoc; 1997 Feb; 210(4):512-6. PubMed ID: 9040837
[TBL] [Abstract][Full Text] [Related]
53. Efficacy of combination chemotherapy for treatment of gastrointestinal lymphoma in dogs.
Rassnick KM; Moore AS; Collister KE; Northrup NC; Kristal O; Chretin JD; Bailey DB
J Vet Intern Med; 2009; 23(2):317-22. PubMed ID: 19192147
[TBL] [Abstract][Full Text] [Related]
54. Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy.
Fisher RI; DeVita VT; Hubbard SM; Longo DL; Wesley R; Chabner BA; Young RC
Ann Intern Med; 1983 Mar; 98(3):304-9. PubMed ID: 6600902
[TBL] [Abstract][Full Text] [Related]
55. MACOP-B versus ProMACE-MOPP in the treatment of advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group.
Sertoli MR; Santini G; Chisesi T; Congiu AM; Rubagotti A; Contu A; Salvagno L; Coser P; Porcellini A; Vespignani M
J Clin Oncol; 1994 Jul; 12(7):1366-74. PubMed ID: 7517442
[TBL] [Abstract][Full Text] [Related]
56. Etoposide, vinblastine, and doxorubicin: an active regimen for the treatment of Hodgkin's disease in relapse following MOPP. Cancer and Leukemia Group B.
Canellos GP; Petroni GR; Barcos M; Duggan DB; Peterson BA
J Clin Oncol; 1995 Aug; 13(8):2005-11. PubMed ID: 7636541
[TBL] [Abstract][Full Text] [Related]
57. BCVPP chemotherapy for advanced Hodgkin's disease: evidence for greater duration of complete remission, greater survival, and less toxicity than with a MOPP regimen. Results of the Eastern Cooperative Oncology Group study.
Bakemeier RF; Anderson JR; Costello W; Rosner G; Horton J; Glick JH; Hines JD; Berard CW; DeVita VT
Ann Intern Med; 1984 Oct; 101(4):447-56. PubMed ID: 6089632
[TBL] [Abstract][Full Text] [Related]
58. Ten years' experience with four cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, prednisone, procarbazine (BEACOPP)-escalated followed by four cycles of baseline-dose BEACOPP in patients with advanced stage Hodgkin lymphoma: a single-center, retrospective study.
Belada D; Štěpánková P; Sýkorová A; Žák P; Smolej L
Leuk Lymphoma; 2015 Jul; 56(7):2013-8. PubMed ID: 25330440
[TBL] [Abstract][Full Text] [Related]
59. Vinblastine, bleomycin, and cis-platin as salvage therapy for MOPP treated patients with Hodgkin's lymphoma.
Corder MP; Clamon GH; Wiesenfeld M
Cancer Invest; 1984; 2(3):193-8. PubMed ID: 6203626
[TBL] [Abstract][Full Text] [Related]
60. Spermatogenesis in Hodgkin's lymphoma patients: a retrospective study of semen quality before and after different chemotherapy regimens.
Paoli D; Rizzo F; Fiore G; Pallotti F; Pulsoni A; Annechini G; Lombardo F; Lenzi A; Gandini L
Hum Reprod; 2016 Feb; 31(2):263-72. PubMed ID: 26705149
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
